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Probiotics have potential to improve host immunity; however, there is less evidence showing their efficacy against infections and nutritional status
in the elderly. We conducted a double-blinded feeding trial in the elderly to elucidate the effect of fermented milk containing Lactobacillus john-
sonii La1 (LC1w) on infections and nutritional status. Twenty-four completely enterally fed elderly in-patients aged over 70 years were randomly
assigned into two groups. All subjects were administered 3768 kJ (900 kcal)/d of total enteral nutrition (EN) through tube feeding for 12 weeks.
Subjects in the LC1 group were administered 373 kJ (89 kcal)/d of LC1 fermented milk after feeding of 3395 kJ (811 kcal)/d of EN for 12 weeks.
In the control group, 373 kJ/d of the same EN was replaced from the fermented milk. In the LC1 group, the percentage of days with infections
during the run-in observation period was 15·4 (SD 17·3) %, which significantly decreased to 5·7 (SD 8·1) % during the intervention period
(P¼0·018), and the reduction was larger than that of the control group (P¼0·047). Blood Hb increased (P,0·05), and there was a tendency
towards an increase in serum albumin and a decrease in TNF-a (a pro-inflammatory cytokine) in the LC1 group. There was a trend towards
an increase in blood phagocytic activity (a natural immunity marker) in the subjects whose initial level was low in the LC1 group. There were
no changes in those parameters in the control group. Administration of fermented milk containing the probiotic L. johnsonii La1 may contribute
to suppressing infections by improving nutritional and immunological status in the elderly.
Human studies: Elderly enterally fed in-patients: Probiotics: Infection: Nutritional status
The proportion of elderly amongst many Western populations
is increasing; for example, the proportion of individuals aged
over 65 years in Japan is 20%, and is estimated to increase to
26% in 20151. Accordingly, healthcare expenditure is increas-
ing, which becomes a socio-economic issue2. Morbidity and
mortality by infectious diseases are high in the elderly3,
where natural defence systems including immune functions
are compromised, which give a primary cause of increase in
disease risks4,5. Nutritional status decreases in the elderly,
especially in hospitalised and enterally fed elderly6,7, which
also causes dysregulation of the immune system8,9. Longevity
may be associated with genotype of pro- and anti-inflamma-
tory cytokines, TNF-a and IL-10 production10, suggesting
that inflammation, a component of immunity, may also have
an influence on health in the elderly. Several research
groups have demonstrated that nutritional supplementation
using micronutrients and/or fish oil improves immune function
and frequency of infections11–13, but the effects are some-
times not or partially observed14,15.
The intestinal microbiota play a key role in providing
defence systems called colonisation resistance16 to keep out
invading pathogenic bacteria. Changes in intestinal microbiota
balance are reported in the elderly17,18, which may attenuate
the host defence19. Probiotics, defined as live micro-organisms
which when administered in adequate amounts confer a health
benefit on the host20,21, are potential measures to regulate
infections in the elderly. Some probiotic bacteria have been
shown to improve host immunity22 and incidence of infections
such as infectious diarrhoea in infancy23 and respiratory infec-
tions in children and adults24,25. It has been shown recently
that administration of a Lactobacillus strain for 3 weeks
reduced the duration of winter infection in free-living
elderly26. The WHO suggested that probiotics are helpful in
normalising nutritional status in children27; however, there is
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less information of the impact of probiotics on nutritional
status in the elderly, especially in combination with other
health-status changes including infection, immune status and
intestinal microbiota.
Lactobacillus johnsonii La1 (NCC533) is a probiotic strain
which is adhesive onto intestinal epithelial cells28 and pro-
duces bactericidal compounds against harmful bacteria such
as Salmonella29. Feeding of fermented milk containing
L. johnsonii La1 has been demonstrated to reinforce human
leucocyte phagocytic activity30, antigen-specific IgA antibody
production in healthy adults31, and improve intestinal micro-
biota to enrich bifidobacteria in healthy adults32. The
immune modification by the La1 strain also regulates inflam-
matory responses, the production of pro-inflammatory
cytokines in vitro is suppressed33,34 and gastric inflammation
is reduced by its intake in Helicobacter pylori-infected
human subjects35,36. Therefore, the probiotic strain has
potential to improve the health status of elderly, whose
immunological status may be compromised and who are
prone to suffer from infectious diseases.
To reveal the effect of fermented milk containing the
probiotic L. johnsonii La1 on the incidence of infection,
immunological and nutritional status, and intestinal microbiota
in elderly subjects, we conducted a 12-week feeding trial in a
randomised double-blind controlled manner on bed-ridden
elderly subjects being fed total enteral nutrition (EN) in hospi-
tal, whose food intake was nutritionally standardised.
Materials and methods
Subjects
The trial was conducted in accordance with the Helsinki
declaration (2000) and the protocol was approved by the Ethi-
cal Committee of Harunaso Hospital (Gunma, Japan). Elderly
volunteers were enrolled from bed-ridden in-patients over 70
years of age at Harunaso Hospital suffering from dysphasia
with dementia and fed total EN by nasogastric tube or gastro-
stomy. After obtaining the agreement of the volunteers and
their family members on the objectives and the design of
the study, seven men and seventeen women (age 75–96
years) were enrolled.
Study design and diet
The study was conducted during the winter season of 2002–3.
Subjects were randomly assigned to two groups, the L. john-
sonii La1 (LC1) and control groups, and a double-blind con-
trolled study was conducted. The profile of the subjects is
shown in Table 1. Test fermented milk (LC1w; Nestle´ Japan
Ltd, Tokyo, Japan) contained the probiotic strain L. johnsonii
La1 (NCC533) at 109 colony-forming units and a non-probio-
tic strain Streptococcus thermophilus at 108 colony-forming
units/90 g. In the run-in observation period for the first 12
weeks, all subjects were administered total EN at 3768 kJ
(900 kcal)/d (CZ-Hi; Clinico Co., Ltd, Tokyo, Japan). In the
intervention period for the subsequent 12 weeks, subjects in
the LC1 group (n 12) were administered 90 g (373 kJ
(89 kcal)) fermented milk through a tube after feeding of EN
at 3395 kJ (811 kcal)/d. The fermented milk was served in a
liquid form by mixing it with water in a kitchen, as we did
for the control EN preparation, in order to maintain blind con-
ditions. The subjects in the control group were administered
the EN diet at 3395 kJ (811 kcal)/d, then administered 373 kJ
(89 kcal) of the EN in the same manner as the fermented
milk in the LC1 group. The diets in the two groups were nutri-
tionally comparable (Table 2).
All subjects were under nursing care during the entire study
period. Health-status parameters including body temperature,
faecal condition (the shape of faeces and stool extraction or
usage of laxatives for defaecation) and usage of drugs were
recorded on a daily basis. Blood and faecal samples were col-
lected before and during the intervention period to assess
nutritional and immune status. The number of days of infec-
tion was counted when the subjects were diagnosed by a phys-
ician as suffering from infections requiring prescribed
antibiotics. Infection, for which antibiotics are prescribed, is
frequently observed in the elderly, and we did not exclude
such subjects in our study design and continued the obser-
vation and sampling. A physician comprehensively diagnosed
respiratory, intestinal or urinary tract infection taking into
account respiratory inflammation, appearance of sputum,
coughing and sneezing, turbidity of urine, watery defaecation
and fever. Duration of infections was expressed in percentage
of days with infections for 12 weeks.
Blood and faecal analysis
Blood samples were collected from the femoral artery at
three time points: just before starting the intervention period
(week 0), and at 4 and 12 weeks during that period. Serum
total protein, albumin, total cholesterol, creatinine, aspartate
aminotransferase, alanine aminotransferase, blood urea nitro-
gen, C-reactive protein, IgG and IgA were measured using a
Hitachi 7600 autoanalyser (Hitachi, Tokyo, Japan), and blood
cell numbers were measured with an SE-9000 autoanalyser
(Sysmex, Kobe, Japan). Cholinesterase activity was measured
using the butyrylthiocholine-5,50-dithiobis-2-nitrobenzoic acid
colorimetric assay. TNF-a was measured using an ELISA
kit (Japan Immunoresearch Lab, Takasaki, Japan), and
phagocytic activity were measured with a PHAGOTEST kit
(Orpegen Pharma, Heidelberg, Germany) using fluorescein
Table 1. Characteristics of subjects
LC1 group Control group
Subjects (n) 12 12
Males (n) 4 3
Females (n) 8 9
Serum albumin ,35 g/l (n) 6 7
Age (years)
Mean 84·4 84·8
SD 6·2 7·0
Age range (years) 75–95 75–96
Body weight (kg)
Mean 39·0 36·7
SD 2·9 3·9
Major episodes
Cerebrovascular diseases 8 11
Cardiovascular diseases 1 0
Diabetes 2 0
Respiratory diseases 1 1
LC1, Lactobacillus johnsonii La1.
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isothiocyanate-labelled Escherichia coli and a flow cytometric
technique. Phagocytic activity and TNF-a were measured only
at 0 and 4 weeks in order to diminish the burden for the subjects.
Faecal microbiota were analysed according to the method of
Mitsuoka et al.37 with slight modification38. Faecal total bac-
teria, total anaerobes, total aerobes, Bacteroidaceae, Bifidobac-
terium, Clostridium, Enterobacteriaceae, Enterococcus and
Lactobacillus were counted using CDC anaerobe blood, BBE,
lactobacilli-selective, and CCFA agar media (Nippon Becton
Dickinson Co., Ltd, Tokyo, Japan), KM-CW egg yolk, DHL,
and EF agar media (Nissui Pharmaceutical Co., Ltd, Tokyo,
Japan), blood liver and bifidobacteria-selective agar, and sheep
blood agar M58 media (Eiken Chemical Co., Ltd, Tokyo,
Japan), and CPS IPD agar medium (Biomerieux Japan, Tokyo,
Japan). Faecal methicillin-resistant Staphylococcus aureus
were also counted using mannitol salt agar medium (Nissui
Pharmaceutical Co., Ltd), and OPA Staphyrococcus agar
medium (Nippon Becton Dickinson Co., Ltd). Faecal samples
were stored anaerobically using Anaero Pack Kenki (Mitsubishi
Gas Chemical, Tokyo, Japan) at 48C and analysed within 24 h
after defaecation. Decimal dilution series of faecal samples
into anaerobic PBS were prepared and samples were plated on
to selective and non-selective media and incubated under
anaerobic or aerobic conditions. Bacterial species were ident-
ified by colony morphology, gram staining, cell morphology,
aerobic growth and biochemical test for sporulation. The three
and two subjects in the LC1 and control groups, respectively,
who took antibiotics in the 7 d before faecal sampling were
excluded from faecal analysis, because the microbiota are
known to be significantly disturbed by antibiotics39.
Statistical analysis
The results are expressed as mean values and standard devi-
ations. Data were analysed with SPSS 11·0 J software (SPSS
Japan, Tokyo, Japan). Statistical differences between the
LC1 and control groups, and between before and during inter-
vention periods were examined using the Wilcoxon rank sum
test. Statistical difference on the appearance ratio of faecal
bacteria was examined with the x2 test. The difference
between means was considered significant at P,0·05.
Results
Clinical observations
All subjects accepted the diet well with or without fermented
milk containing L. johnsonii La1 and no adverse health con-
ditions were observed during the entire study period. No sub-
jects received any vaccination in the study periods. Table 3
and Fig. 1 show the duration of infections and the health
status of the subjects. There was no difference in duration of
infections, diarrhoea or fever during the observation period
between the LC1 and control groups. In the LC1 group, the
duration of infections (percentage of days) in the observation
period was 15·4 (SD 17·3) %which significantly lowered to 5·7
(SD 8·1) % in the intervention period (P¼0·018), and the
reduction was larger in the LC1 group than that in the control
group (P¼0·047). Respiratory symptoms were most fre-
quently found, and they improved in the LC1 group, but inci-
dence of the others without respiratory symptoms was low and
such improvement was undetectable. Decrease in the duration
of fever at .378C tended to be larger in the LC1 group than
that in the control group (P¼0·078). In the control group,
there were no differences in the duration of infection or
fever between the two periods. There were no changes in
defaecation conditions including usage of laxatives and
watery faecal excretion not caused by laxatives in both
groups during the entire study period (Table 3).
Nutritional and immunological status
The changes in nutritional status and the other blood biomarkers
are shown in Table 4. Hb concentration in blood increased in the
LC1 group, and was significantly higher than that of the control
group at 4 weeks (P¼0·038). There were no statistical differ-
ences between the LC1 group and the control group for other
blood biomarkers, but changes were observed within the LC1
group; that is; serumalbumin at 12weeks during the intervention
period was higher (P¼0·034) than that before intake (week 0),
cholinesterase increased at 4 weeks (P¼0·028) and remained
at a similar level at week 12, and total protein tended to increase
from 0 to 12 weeks (P¼0·052). Erythrocyte and leucocyte num-
bers increased at 4 weeks and 12 weeks in the LC1 group,
Table 2. Daily intake of energy and nutrients
Observation period
Intervention period
All subjects LC1 group (EN þ LC1) Control group (EN)
Total energy (kJ/d) 3768 3768 3768
Total energy (kcal/d) 900 900 900
Cz-Hi (Clinico Co. Ltd) (kJ/d) 3768 3395 3768
Cz-Hi (kcal/d) 900 811 900
LC1 yogurt (Nestle´ Japan Ltd)* (kJ/d) 0 373 0
LC1 yogurt* (kcal/d) 0 89 0
Protein (g/d) 45 45 45
Lipid (g/d) 20 20 20
Carbohydrates (g/d) 136 136 135
Dietary fibre (g/d) 18 16 18
Zn (mg/d) 10 9 10
Oligosaccharides (g/d) 0·5 0·4 0·5
DHA þ EPA (g/d) 0·5 0·4 0·5
LC1, Lactobacillus johnsonii La1; EN, enteral nutrition.
* LC1 yogurt contains 109 colony-forming units Lactobacillus johnsonii La1/90 g.
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Table 3. Infection, body temperature and faecal conditions in elderly subjects
(Mean values and standard deviations)
LC1 group (n 12) Control group (n 12)
Observation period
(211 to 0 weeks)‡
Intervention period
(1 to 12 weeks) Difference
Observation period
(–11 to 0 weeks)‡
Intervention period
(1 to 12 weeks) Difference
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
Body temperature (8C) 36·75 0·39 36·76 0·42 0·02 0·16 36·83 0·36 36·89 0·35 0·06 0·35
Duration of fever (% of days in 12 weeks)
.37·08C 27·4 19·0 23·4 14·5 24·0 15·0 29·1 22·8 37·1 23·3 8·1 18·7
.37·58C 4·7 6·1 3·9 3·2 20·8 4·4 4·9 7·0 7·1 8·1 2·2 5·9
.38·08C 1·9 2·7 1·6 1·7 20·4 1·7 0·1 0·3 1·1 2·8 1·0 2·9
Duration of infection (% of days in 12 weeks) 15·4 17·3 5·7* 8·1 29·6† 10·9 13·7 21·5 10·7 14·7 23·0 14·7
Defaecation (% of days in 12 weeks)
Normal 27·4 21·4 23·1 20·8 24·3 20·9 23·7 19·6 26·6 25·0 2·9 16·6
Extraction 3·7 4·7 5·5 5·1 1·9 2·6 0·9 1·5 2·1 2·3 1·2 1·9
Laxative 21·1 13·6 24·3 22·7 3·2 14·3 29·7 24·4 25·7 26·9 23·9 19·1
Watery 2·2 3·1 1·6 2·9 20·6 4·5 0·9 2·5 4·9 11·6 4·0 9·4
Total 54·5 16·9 54·6 20·5 0·1 17·5 55·2 13·1 59·3 18·4 4·2 18·7
LC1, Lactobacillus johnsonii La1.
* Mean value was significantly different from that of the same group before administration (P,0·05).
† Mean difference was significantly different from that of the control group (P,0·05).
‡ The run-in observation period was 12 weeks before starting the intervention period for 12 weeks.
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respectively (P,0·05). However, this was not significant
between groups. The ratio of blood cell types remained
unchanged. In the control group, we observed a slight increase
in serum albumin, white blood cells and IgG, but the changes
were not statistically significant, and the other biomarkers
showed no changes. Serum albumin was positively correlated
with cholinesterase and total cholesterol at each time point
(R 0·49–0·67; P,0·01), but not with total protein. Total choles-
terol was slightly increased in the LC1 group, but it was not
significant.
There were no significant changes in blood immune bio-
markers between groups, but the following trends were evi-
dent, before and after treatment in the LC1 group. Blood
phagocytic activity was normal at not less than 90% in
twelve out of twenty-four subjects40. In the LC1 group,
there were six subjects whose initial values were lower than
90%, and they significantly increased from 0 to 4 weeks
(P¼0·046; Table 4). The phagocytic activity in subjects
with initially high values showed no changes. Neutrophils,
the major blood cells providing phagocytic activity, remained
unchanged. Serum TNF-a decreased from 0 to 4 weeks in the
LC1 group (P¼0·008). Such changes were not observed in the
control group (Table 4). There were no differences in serum
immune parameters including total IgG, IgA, and C-reactive
protein between the groups.
Faecal microbiota
The number and proportion of faecal bacteria are shown in
Table 5. Total number of faecal bacteria in the elderly subjects
was approximately 1010 colony-forming units/g wet faeces,
which was about ten times lower than that usually found in
healthy adults37. Bifidobacteria were not found in five out of
nineteen subjects (26%). For both groups, we observed no sig-
nificant changes in faecal microbiota at any time point. Lacto-
bacillus slightly increased in the LC1 group, but this was not
significant. Appearance of methicillin-resistant Staphylococ-
cus aureus decreased from 0 to 12 weeks in the LC1 group
(P¼0·016), according to reduction of antibiotic usage.
Discussion
The present study showed that the duration of infections in
hospitalised, enterally fed elderly subjects was reduced by
the administration of fermented milk containing L. johnsonii
La1 for 12 weeks. Not only nutrition but also exercise and
positive emotion are known to influence the immune
system41,42. In the present study, all subjects were bed-
ridden in-patients treated with total EN, and suffering from
dementia. Their life circumstances were quite similar, nutri-
tionally, mentally and physically. Although the number of
subjects in the study was limited, the homogeneous living con-
ditions and health status of the subjects allowed us to demon-
strate that feeding of fermented milk containing the La1 strain
is a potential way to decrease infections. In the present study,
we used the test fermented milk containing not only the pro-
biotic strain L. johnsonii La1, but also the non-probiotic
strain S. thermophilus, and their fermentated metabolites,
which makes it difficult to conclude whether the anti-infec-
tious effect was provided solely by the probiotic strain.
Dunnet-Huges et al. showed that the elevation of blood phago-
cytic activity in human subjects fed fermented milk containing
S. thermophilus is weaker than that containing the La1
strain43. Cruchet et al. reported that the anti-H. pylori effect
of probiotic feeding with the La1 strain found in children dis-
appeared when the strain was killed by heat treatment36. These
findings suggest that the live probiotic strain may efficiently
exert some health benefits. It is difficult to distinguish the effi-
cacy of the La1 strain from the other elements in the test fer-
mented milk; however, the La1 strain, whose efficacy is well
proven, may more largely contribute or efficiently trigger the
effects we found in the present study. Some researchers have
shown that nutritional supplementation could work to enhance
immunity and suppress infectious diseases11–13, but they did
not always work sufficiently14,15 or needed long-term con-
sumption44,45. The EN formula we used for both the test and
control groups in the present study was already rich in Zn,
vitamins and PUFA, suggesting that probiotic feeding may
work on top of such nutritional supplements for the elderly.
An interesting finding shown in the present study was that
probiotic feeding improved nutritional status, as shown by
the increase in serum albumin. We separately conducted a
human trial on healthy elderly living at a nursing home with
usual meal services, and observed that the administration of
fermented milk containing the La1 strain elevated serum albu-
min46, implying that the use of fermented milk containing the
La1 strain to improve nutritional status could be widely
adopted by the elderly not only with tube feeding but also
with slight malnutrition that frequently occurs in this age
group47. Serum cholinesterase, a marker of liver function,
was also increased by probiotic feeding. These improvements
Fig. 1. Durations of infections (a and b) and fever of more than 37·58C
(c and d) in elderly subjects fed Lactobacillus johnsonii La1 (LC1; n 12; a and
c) and in control subjects (n 12; b and d). Values are means. * Duration of
infections (% of days) during the intervention period was lower than that of
the observation period in the LC1 group (P,0·05).
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Table 4. Blood biomarkers related health, nutritional, and immunological status
(Mean values and standard deviations)
LCI group (n 12) Control group (n 12)
0 weeks 4 weeks 12 weeks 0 weeks 4 weeks 12 weeks
Standard value Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
Nutrition status markers
Total protein (g/l) 65–82 66·7 5·5 68·0 4·8 69·1 4·9 66·2 4·3 66·7 6·1 68·3 4·0
Albumin (g/l) 35–55 34·3 3·2 35·2 2·3 35·8* 2·5 33·9 3·6 33·8 3·0 35·0 3·2
Total cholesterol (mg/l) 1·300–2·500 1·730 0·370 1·780 0·430 1·870 0·450 1·700 0·290 1·630 0·350 1·720 0·350
Immunological status markers
IgG (g/l) – 15 ·930 5·290 16· 600 5·740 16·450 5·620 16·160 3·700 17·460 5·100 17·600 4·300
IgA (g/l) – 3·430 1·650 3·510 1·690 3·370 1·710 4·010 1·980 4·120 1·920 4·170 1·950
Phagocytic activity
All subjects (%) – 86·3 10·7 87·8 4·9 ND 85·7 7·4 83·8 9·0 ND
Subject with low levels (%)‡ – 80·3 12·8 88·0* 6·6 ND 79·8 6·0 77·9 8·9 ND
C-reactive protein (mg/l) 0·0–5·0 14·5 18·7 12·1 15·5 12·5 14·1 13·2 29·0 8·0 9·1 17·7 41·2
TNF-a (pg/ml) – 2·97 2·30 2·27** 2·26 ND 1·78 0·87 1·73 ND
Other blood biomarkers
AST (IU/l) 8–38 26·0 10·1 24·1 8·1 24·0 9·5 25·7 9·9 22·8 6·3 22·8 5·5
ALT (IU/l) 4–44 25·4 18·4 23·0 14·0 23·4 8·9 20·7 12·4 18·4 5·9 19·7 7·2
Cholinesterase (IU/l) 200–400 105 42 114* 42 113 46 102 30 105 32 109 34
BUN (mg/l) 80–210 215 73 225 79 233 96 269 145 296 148 308 143
Creatinine (mg/l) 3–11 5 2 5 2 5 2 7 4 7 4 8 4
White blood cells ( £ 100/ml) 40–80 66·5 27·1 78·6 34·5 77·3* 25·5 58·3 20·8 63·7 9·7 68·1 13·4
Erythrocytes ( £ 10 000/ml) 370–570 359 36 395*† 47 377 40 352 54 330 53 365 47
Hb (g/l) 113–174 111 20 125*† 18 121* 17 113 17 107 16 117 15
Platelets (%) 12–38 28·5 9·6 26·5 10·3 27·8 10·7 25·2 7·4 26·7 7·2 26·1 8·3
Lymphocytes (%) 20–55 25·8 9·3 23·8 7·1 25·7 13·0 25·3 8·7 25·2 8·2 26·0 9·9
Neutrophils (%) 37–73 62·8 11·5 67·3 8·2 63·7 13·6 63·6 11·9 61·8 12·8 60·8 10·4
Eosinophils (%) 0·5–11 3·4 1·8 2·8 2·4 3·7 2·6 4·2 3·2 5·3 7·0 5·2 4·2
Basophils (%) 0–2 0·4 0·3 0·3 0·2 0·5 0·4 0·2 0·2 0·4 0·2 0·3 0·3
LC1, Lactobacillus johnsonii La1; ND, not determined; AST, aspartate aminotransferase; ALT, alanine aminotransferase, BUN, blood urea nitrogen.
Mean value was significantly different from that at 0 weeks: * P,0·05, ** P,0·01.
† Mean difference was significantly different from that of the control group (P,0·05).
‡ Subjects whose basal phagocytic activity was lower than 90 %, LC1 (n 6) and control (n 6).
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could play a key role in the regulation of infections by revita-
lising the immune system and organs. Diarrhoea may cause
malnutrition, which can be reversed by probiotics through
the regulation of diarrhoea by normalising intestinal micro-
biota48. In the present study, however, incidence of diarrhoea
was low from the beginning, and we did not find any changes
in its incidence or faecal microbiota by the probiotic feeding,
indicating that improvement of nutritional status found in
the present study was not likely to have occurred through an
anti-diarrhoeal effect. Recently, we found that duodenal
administration of the La1 strain stimulates the parasympa-
thetic nervous system in vivo49,50. Physiological declines of
gastrointestinal functions, including not only of immunologi-
cal but also neurological and metabolic systems, occur in
aged populations51. The probiotic strain may act as an ana-
bolic stimulus to the intestines through the auto-nervous
system and may revitalise the digestive and absorption sys-
tems. We observed in the present study that the inflammatory
blood parameter TNF-a decreased in the probiotic-fed sub-
jects. The anti-inflammatory action of the La1 strain is also
shown in an in vitro epithelial cell-culture model34. The
decrease in inflammation and fever associated with the regu-
lation of infections might lower the unexpected expenditure
of energy and nutrients of the body. These findings imply
that the intestinal stimulation and anti-inflammatory effects
of the La1 strain might explain the mechanisms of it on the
nutritional status improvement.
Immune reinforcement by probiotics may play a key role in
the reduction of infections. In the present study, blood phago-
cytic activity, a biomarker for natural immunity, increased
with probiotic feeding in the elderly subjects who had low
initial activity. Ageing influences haematopoietic stem cells
and lymphocytes52 and we found slight recovery of blood
cell numbers in the subjects of the LC1 group. Probiotics, as
bacteria, potentially stimulate the host immunity directly22,30,
after being recognised by the host through antigen-presenting
cells such as dendritic cells in the intestinal tract53 and at the
Payer’s patches54, or through intestinal epithelial cells cover-
ing the huge surface of the intestine33. The decrease in infec-
tions found in the present study may be totally caused by
nutritional status improvement, immune enhancement and
anti-inflammation, which were triggered by feeding of the fer-
mented milk containing the La1 probiotic strain.
In healthy children and adults, probiotic feeding generally
exerts intestinal microbiota improvement and other effects
such as immune reinforcement at the same time, and it is there-
fore difficult to distinguish the direct effect of the probiotic strain
from the indirect effect through growth of residential bacteria
influenced by probiotic feeding. Interestingly, the present
study provides the evidence that feeding of fermented milk con-
taining a single probiotic strain may improve nutritional status
and immunity without any help of proportional changes in the
residential bacteria. It is a common finding that the adminis-
tration of lactobacilli results in an increase in bifidobacteria32,55,
where a huge variety of bacterial strains are involved in changing
intestinal microbial ecology. While we expected to improve
intestinal microbiota in the elderly with poor bacterial mass
and diversity, especially in total enterally fed subjects7, not
just a single strain but a probiotic cocktail or combination with
prebiotics56 could be needed to provide the missing links in
the chain of bacterial metabolite–growth elements network.T
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In spite of observing no changes in faecalmicrobiota, the present
study showed that probiotic feeding suppressed the appearance
of the faecal antibiotic-resistant strain methicillin-resistant Sta-
phylococcus aureus, which may cause opportunistic infec-
tions57. Probiotic feeding could therefore be beneficial in the
elderly not only to reduce the incidence of infections but also
to reduce the negative impact of antibiotics used in medical
facilities. These effects could be directly provided by probiotic
feeding, independently from indirect influence through intesti-
nal microbiota.
In conclusion, feeding of the probiotic L. johnsonii La1 on
top of a well-designed nutritional supplement may reduce the
risk of infections through improvement of nutritional status
and immune function in the elderly, contributing to improve-
ment in their quality of life.
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